Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Jan 17

PMID 30646574

Citations 69

Authors

Jianguang Zhang

Huifang Zheng

Yong Diao

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy.

Citing Articles

Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L Bioeng Transl Med. 2025; 10(2):e10716.

PMID: 40060757 PMC: 11883117. DOI: 10.1002/btm2.10716.

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma.

Nakamura M, Tanaka Y, Hakoda K, Ohira M, Kobayashi T, Kurachi K Cancer Immunol Immunother. 2025; 74(3):99.

PMID: 39904787 PMC: 11794780. DOI: 10.1007/s00262-025-03940-5.

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.

Zhu X, Xue J, Jiang H, Xue D Mol Cancer. 2024; 23(1):237.

PMID: 39443938 PMC: 11515662. DOI: 10.1186/s12943-024-02151-3.

Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.

Kheirkhah A, Habibi S, Yousefi M, Mehri S, Ma B, Saleh M Front Immunol. 2024; 15:1460437.

PMID: 39411712 PMC: 11474923. DOI: 10.3389/fimmu.2024.1460437.

References

Sivakumar P, Gunturi A, Salcedo M, Schatzle J, Lai W, Kurepa Z . Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development. J Immunol. 1999; 162(12):6976-80. View

Tam Y, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann H . Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999; 10(8):1359-73. DOI: 10.1089/10430349950018030. View

Tam Y, Miyagawa B, Ho V, Klingemann H . Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother. 1999; 8(3):281-90. DOI: 10.1089/106161299320316. View

Waring P, Mullbacher A . Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999; 77(4):312-7. DOI: 10.1046/j.1440-1711.1999.00837.x. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

Yagita M, Huang C, Umehara H, Matsuo Y, Tabata R, Miyake M . A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000; 14(5):922-30. DOI: 10.1038/sj.leu.2401769. View

Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A . Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001; 97(3):708-13. DOI: 10.1182/blood.v97.3.708. View

Maki G, Klingemann H, Martinson J, Tam Y . Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001; 10(3):369-83. DOI: 10.1089/152581601750288975. View

Tonn T, Becker S, Esser R, Schwabe D, Seifried E . Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001; 10(4):535-44. DOI: 10.1089/15258160152509145. View

10.

Cooper M, Fehniger T, Caligiuri M . The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22(11):633-40. DOI: 10.1016/s1471-4906(01)02060-9. View

11.

Wajant H . The Fas signaling pathway: more than a paradigm. Science. 2002; 296(5573):1635-6. DOI: 10.1126/science.1071553. View

12.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann H . Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002; 100(4):1265-73. View

13.

Gilfillan S, Ho E, Cella M, Yokoyama W, Colonna M . NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol. 2002; 3(12):1150-5. DOI: 10.1038/ni857. View

14.

Fehniger T, Cooper M, Nuovo G, Cella M, Facchetti F, Colonna M . CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2002; 101(8):3052-7. DOI: 10.1182/blood-2002-09-2876. View

15.

Le Bouteiller P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A, Aguerre-Girr M . Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A. 2002; 99(26):16963-8. PMC: 139252. DOI: 10.1073/pnas.012681099. View

16.

Trinchieri G . The choices of a natural killer. Nat Immunol. 2003; 4(6):509-10. DOI: 10.1038/ni0603-509. View

17.

Tam Y, Martinson J, Doligosa K, Klingemann H . Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003; 5(3):259-72. DOI: 10.1080/14653240310001523. View

18.

Yoneda N, Tatsumi E, Kawano S, Teshigawara K, Oka T, Fukuda M . Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. Leukemia. 1992; 6(2):136-41. View

19.

Chen I, Whalen M, Bankhurst A, Sever C, Doshi R, Hardekopf D . A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization. Leuk Res. 2003; 28(3):275-84. DOI: 10.1016/s0145-2126(03)00254-6. View

20.

Isobe Y, Sugimoto K, Yang L, Tamayose K, Egashira M, Kaneko T . Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res. 2004; 64(6):2167-74. DOI: 10.1158/0008-5472.can-03-1562. View